NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.88+0.18 (+2.76%)
Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%
NextCure revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
NextCure's revenue for the twelve months ending Dec 31, 2020 was $22.38M, up 252.6% year over year. For fiscal 2020 it was $22.38M, up 252.6% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $22.38M | +252.6% |
| FY2019 | Dec 31, 2019 | $6.35M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2020 | Dec 31, 2020 | $0 | -100.0% |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | -100.0% |
| Q1 FY2020 | Mar 31, 2020 | $22.38M | +1549.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.01M | – |
| Q3 FY2019 | Sep 30, 2019 | $1.58M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.40M | – |
| Q1 FY2019 | Mar 31, 2019 | $1.36M | – |
See a number that looks wrong?